Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Program entities : Qualigen therapeutics, inc. save search
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Published: 2023-05-02 (Crawled : 12:20) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: 5.15%
H: 7.14%
C: 2.03%
meeting program
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
Published: 2023-03-09 (Crawled : 15:00) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: -1.71%
H: 2.61%
C: -1.23%
conference association program therapeutics cancer
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
Published: 2023-03-08 (Crawled : 13:20) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: 1.59%
H: 3.13%
C: -8.59%
qn-302 program biomarker potential
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
Published: 2022-10-19 (Crawled : 13:00) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: -3.01%
H: 4.59%
C: -1.76%
program therapeutics cancer
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
Published: 2022-06-07 (Crawled : 13:20) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: -1.54%
H: 4.48%
C: -1.1%
qn-302 trials program therapeutics trial
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: 5.45%
H: 1.98%
C: -1.72%
program research therapeutics
Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: 0.41%
H: 4.51%
C: 0.75%
qn-302 program conference therapeutics presentation
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: -0.33%
H: 9.61%
C: 1.53%
qn-302 program therapeutics
Associate Director Program Management
Published: 2021-10-21 (Crawled : 18:00) - qualigeninc.com
QLGN | $0.2953 8.6K
|
Health Technology
|
| O: -1.69%
H: 5.5%
C: 3.45%
program
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.21 41.67% 5.6M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.